Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute...

Availability in Both Intravenous and Oral Formulation is a Leading Drug
Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract
Infections in the Hospital Setting

Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use of
Carbapenems In the Next Five Years, According to a New Report from AMR and
Decision Resources

MALVERN, Pa. and WALTHAM, Mass., June 24 /PRNewswire/ -- Arlington Medical
Resources (AMR) and Decision Resources find that availability in both
intravenous and oral formulation is a leading drug attribute that surveyed
physicians prefer for the treatment of complicated urinary tract infections
(UTIs) in the hospital setting. Antibiotics available in interchangeable oral
and parenteral formulations can facilitate step-down therapy and discharge
from the hospital to the outpatient setting.

"Physicians prescribe a wide variety of antibiotics for UTIs, mainly from the
quinolone and cephalosporin classes," stated Lisa Arias, analyst at Decision
Resources. "These broad-spectrum agents are popular first-line agents in UTIs,
and oral quinolones, in particular, have become a popular choice for
first-line, step-down and discharge therapy."

The new report entitled Hospital Anti-Infectives Insight Series: Urinary Tract
Infections also finds that extended-spectrum beta-lactamase-producing and
quinolone-resistant gram-negative pathogens are among the most concerning
pathogens, and that 77 percent of surveyed physicians expect to increase their
prescribing of carbapenems for complicated UTIs in the next five years. These
potent, broad-spectrum antibiotics are especially useful for treating
gram-negative infections involving resistant organisms.

About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes
hospital antibiotic prescribing patterns using AMR's comprehensive and highly
detailed clinical data in conjunction with Decision Resources' disease area
knowledge, primary research and extensive understanding of emerging therapies
and forecasts. These reports examine the reasons behind physicians' product
preferences, factors driving hospital antibiotic prescribing patterns and
receptivity to emerging antibiotics.

About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the
pharmaceutical and diagnostic imaging industries. Research includes clinical
inpatient databases that directly link anti-infective drug with
indication/procedure, formulary and stocking status tracking studies, drug
purchasing audits and diagnostic imaging procedure volume/contrast media usage
audits. AMR is a Decision Resources, Inc. company.

About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:
Gisselle Morales
Decision Resources
781-296-2691
gmorales@dresources.com

Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com

SOURCE Decision Resources; Arlington Medical Resources

Gisselle Morales, +1-781-296-2691, gmorales@dresources.com, or Elizabeth
Marshall, +1-781-296-2563, emarshall@dresources.com, both of Decision
Resources, Inc.